85 related articles for article (PubMed ID: 19271027)
1. Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.
Madaan A
Drugs Today (Barc); 2009 Jan; 45(1):3-9. PubMed ID: 19271027
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
4. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.
Loh CH; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Mar; 14(3):463-72. PubMed ID: 25563342
[TBL] [Abstract][Full Text] [Related]
5. Nebulized arformoterol: what is its place in the management of COPD?
Miles MC; Donohue JF; Ohar JA
Ther Adv Respir Dis; 2013 Apr; 7(2):81-6. PubMed ID: 23147985
[TBL] [Abstract][Full Text] [Related]
6. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy V; Stensland MD
Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
[TBL] [Abstract][Full Text] [Related]
7. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
8. Arformoterol tartrate in the treatment of COPD.
Cazzola M; Hanania NA; Matera MG
Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
[TBL] [Abstract][Full Text] [Related]
10. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue JF; Hanania NA; Make B; Miles MC; Mahler DA; Curry L; Tosiello R; Wheeler A; Tashkin DP
Chest; 2014 Dec; 146(6):1531-1542. PubMed ID: 25451347
[TBL] [Abstract][Full Text] [Related]
11. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA
COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972
[TBL] [Abstract][Full Text] [Related]
12. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
Celli BR; Navaie M; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
Int J Chron Obstruct Pulmon Dis; 2019; 14():1019-1031. PubMed ID: 31190787
[No Abstract] [Full Text] [Related]
13. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
[TBL] [Abstract][Full Text] [Related]
14. Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol.
Drugs R D; 2004; 5(1):25-7. PubMed ID: 14725487
[TBL] [Abstract][Full Text] [Related]
15. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
[TBL] [Abstract][Full Text] [Related]
16. Role of arformoterol in the management of COPD.
King P
Int J Chron Obstruct Pulmon Dis; 2008; 3(3):385-91. PubMed ID: 18990965
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
19. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
20. The use of inhaled formoterol in the treatment of asthma.
Berger WE
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
